tetano
Editor, Senior Moderator
Rheumatol Ther
. 2024 Jan 4.
doi: 10.1007/s40744-023-00630-5. Online ahead of print. Safety and Efficacy of Inactivated SARS-CoV-2 Vaccine in Patients with Rheumatic Diseases and Serum Antibody Changes Post-Omicron Variant Infection
Xiaowei Zhang[SUP] #[/SUP][SUP] 1 [/SUP], Yifei Li[SUP] #[/SUP][SUP] 2 [/SUP], Chunqing Dai[SUP] #[/SUP][SUP] 3 [/SUP], Yaya Chu[SUP] 2 [/SUP], Chaoqi Luan[SUP] 4 [/SUP], Guihong Wang[SUP] 5 [/SUP]
Affiliations
Introduction: The purpose of this study was to investigate whether the inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine has a similar effectiveness and safety profile in patients with rheumatic and musculoskeletal diseases (RMDs) and healthy controls (HCs).
Methods: Between August 10, 2021 and September 30, 2021, 134 HCs and 269 patients with RMDs were recruited. All participants who tested negative for COVID-19 were vaccinated with SARS-CoV-2 inactivated vaccine. Next, 150 patients with RMDs and 30 HCs infected with the SARS-CoV-2 Omicron variant within the previous 12 weeks were recruited between February 20, 2023 and March 1, 2023. Serum samples were collected from each participant, and the serum immunoglobulin G (IgG) and immunoglobulin M (IgM) antibody titers against SARS-CoV-2 were determined using a chemiluminescence assay.
Results: No statistically significant difference was found in the titer of anti-SARS-CoV-2 IgG and IgM antibodies, or in the incidence of vaccination-related adverse events between the RMD and HC groups (P = 0.183, P = 0.903, and P = 0.27, respectively). Serum IgG titers of SARS-CoV-2 neutralizing antibodies were significantly higher in patients who received two or more doses of inactivated vaccine than in patients who were unvaccinated or had received one dose of vaccine (244.36 ± 109.79 vs. 66.20 ± 82.50; P < 0.001).
Conclusions: SARS-CoV-2 inactivated vaccines have similar protective effects in HCs and patients with RMDs, with an appreciable safety profile. Fully vaccinated patients with RMDs infected with the Omicron variant were able to produce effective neutralizing antibody concentrations.
Keywords: Adverse events; Musculoskeletal diseases; Omicron variant; Rheumatic diseases; SARS-CoV-2 vaccine; Serum antibodies.
. 2024 Jan 4.
doi: 10.1007/s40744-023-00630-5. Online ahead of print. Safety and Efficacy of Inactivated SARS-CoV-2 Vaccine in Patients with Rheumatic Diseases and Serum Antibody Changes Post-Omicron Variant Infection
Xiaowei Zhang[SUP] #[/SUP][SUP] 1 [/SUP], Yifei Li[SUP] #[/SUP][SUP] 2 [/SUP], Chunqing Dai[SUP] #[/SUP][SUP] 3 [/SUP], Yaya Chu[SUP] 2 [/SUP], Chaoqi Luan[SUP] 4 [/SUP], Guihong Wang[SUP] 5 [/SUP]
Affiliations
- PMID: 38175331
- DOI: 10.1007/s40744-023-00630-5
Introduction: The purpose of this study was to investigate whether the inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine has a similar effectiveness and safety profile in patients with rheumatic and musculoskeletal diseases (RMDs) and healthy controls (HCs).
Methods: Between August 10, 2021 and September 30, 2021, 134 HCs and 269 patients with RMDs were recruited. All participants who tested negative for COVID-19 were vaccinated with SARS-CoV-2 inactivated vaccine. Next, 150 patients with RMDs and 30 HCs infected with the SARS-CoV-2 Omicron variant within the previous 12 weeks were recruited between February 20, 2023 and March 1, 2023. Serum samples were collected from each participant, and the serum immunoglobulin G (IgG) and immunoglobulin M (IgM) antibody titers against SARS-CoV-2 were determined using a chemiluminescence assay.
Results: No statistically significant difference was found in the titer of anti-SARS-CoV-2 IgG and IgM antibodies, or in the incidence of vaccination-related adverse events between the RMD and HC groups (P = 0.183, P = 0.903, and P = 0.27, respectively). Serum IgG titers of SARS-CoV-2 neutralizing antibodies were significantly higher in patients who received two or more doses of inactivated vaccine than in patients who were unvaccinated or had received one dose of vaccine (244.36 ± 109.79 vs. 66.20 ± 82.50; P < 0.001).
Conclusions: SARS-CoV-2 inactivated vaccines have similar protective effects in HCs and patients with RMDs, with an appreciable safety profile. Fully vaccinated patients with RMDs infected with the Omicron variant were able to produce effective neutralizing antibody concentrations.
Keywords: Adverse events; Musculoskeletal diseases; Omicron variant; Rheumatic diseases; SARS-CoV-2 vaccine; Serum antibodies.